Press release from PR Newswire
Atrium Innovations Announces Acquisition of Enzimas S.A.
Thursday, August 18, 2011
Atrium Innovations Announces Acquisition of Enzimas S.A.10:12 EDT Thursday, August 18, 2011 Vertical integration acquisition aimed at securing strategic enzymes for Wobenzym product formulation QUEBEC CITY, Aug. 18, 2011 /PRNewswire/ - Atrium Innovations Inc. (TSX: ATB), a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today announced the acquisition of Enzimas S.A., a manufacturer of Trypsin and Chymotrypsin enzymes based in Lujan, Argentina. Through this transaction, the Company acquires a manufacturing facility and process that is approved by various regulatory bodies in countries where Wobenzym products are sold. This acquisition was aimed at securing two critical enzymes, which are in relatively short supply worldwide in the quality required for the formulation of Wobenzym products. Furthermore, the transaction is supported by an attractive potential return on investment based on anticipated manufacturing cost savings. About Atrium Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products endorsed by health professionals. The Company distributes its extensive portfolio of products mainly in the healthcare practitioner and health food and specialized store channels, with a primary focus in North America and Europe. Atrium is at the forefront of science, innovation and education in the dietary supplement industry. The Company has over 1,000 employees and operates seven manufacturing facilities. Additional information is available at www.atrium-innovations.com. About Enzimas S.A. Enzimas S.A. is a manufacturer of Trypsin and Chymotrypsin extracted from bovine and porcine glands. It is the only BfArM (German Federal Institute for Drugs and Medical Devices) accredited supplier of those enzymes and was the exclusive supplier of Trypsin and Chymotrypsin to Atrium Group. The company has approximately 50 employees and operates a facility in Lujan, Argentina. Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks, may involve, but are not limited to, comments with respect to the Company's business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations and future contingent payments. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. The Company considers these assumptions to be reasonable based on information currently available to it, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this press release, see the Company's quarterly and annual Management Discussion and Analysis for the fiscal year ended December 31, 2010 filed with the Canadian securities commissions. The forward-looking information set forth herein reflects the Company's expectations as at the date of this press release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law. SOURCE ATRIUM INNOVATIONS INC.For further information: <table valign="top" border="0"> <tr> <td align="left"> <b>Investor Relations</b>: <br/> Mario Paradis<br/> Vice President and Chief Financial Officer<br/> Tel.: 418 652-1116<b> </b><br/> <a href="mailto:firstname.lastname@example.org" font-weight="bold">email@example.com</a><b> </b> </td> <td align="left" valign="top"> <b>Media Relations:</b><br/> Amélie Germain<br/> Director of Communications<br/> Tel.: 418 652-1116<b> </b><br/> <a href="mailto:firstname.lastname@example.org" font-weight="bold">email@example.com</a><b> </b> </td> </tr> <tr> <td align="left"> </td> <td align="right"> </td> </tr> <tr> <td align="left"> Pierre Boucher<br/> MaisonBrison Communications<br/> Tel.: 514 731-0000, ext. 237<br/> <a href="mailto:firstname.lastname@example.org">email@example.com</a> </td> </tr> </table> <p> </p>